Compound: IMIQUIMOD
SMILES: n1c(N)c2ncn(c2c3c1cccc3)CC(C)C
InChIKey: DOUYETYNHWVLEO-UHFFFAOYSA-N
Synonyms: IMIQUIMOD, 99011-02-6, Aldara, 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, Zyclara, 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine, 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline, R 837, R-837, S-26308, 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline, TMX-101, Imiquimodum, DTXSID7041047, S 26308, S26308, NSC-369100, NSC-759651, P1QW714R7M, TMX 101, 1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-, R837, 1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-, DTXCID5021047, CHEBI:36704, 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine, NSC369100, 1-(2-methylpropyl)-1H-imidazo(4,5-c)quinolin-4-amine, RefChem:57767, D06BB10, NSC741062, 619-387-8, Beselna, 9050-31-1, 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine, (Hydroxypropyl)methyl cellulose phthalate, MFCD00866946, 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine, 1-isobutylimidazo[4,5-c]quinolin-4-amine, CHEMBL1282, NCGC00070736-02, Zartra, Imiquimod acetate, Hpmcp, Aldara (TN), CAS-99011-02-6, SR-01000611320, UNII-P1QW714R7M, Imiqimod, Imiquimod [USAN:INN:BAN], Vyloma, imiquimod?, MTD-39, HSDB 8129, 6T0, Zyclara (TN), Imiquimod (Standard), DZ-2636, Hydroxypropyl Methyl Cellulose Phthalate, IMIQUIMOD [INN], IMIQUIMOD [JAN], IMIQUIMOD [MI], IMIQUIMOD [USAN], IMIQUIMOD [VANDF], Hypromellose phthalate CRS, IMIQUIMOD [MART.], Cellulose, hydrogen 1,2-benzenedicarboxylate, 2-hydroxypropyl methyl ether, IMIQUIMOD [USP-RS], IMIQUIMOD [WHO-DD], Imiquimod (JAN/USP/INN), 4-amino- 1-isobutyl-1h-imidazo[4,5-c]quinoline, SCHEMBL26136, IMIQUIMOD [EMA EPAR], MLS000083577, BIDD:GT0859, Imiquimod - Bio-X trade mark, GTPL5003, orb1310904, orb3025454, IMIQUIMOD [ORANGE BOOK], SCHEMBL29357252, HY-B0180R, IMIQUIMOD [USP MONOGRAPH], GLXC-05818, HMS2090M14, HMS2232G07, HMS3373B13, HMS3715N19, HMS3747A13, HMS5087E15, Pharmakon1600-01502351, ALBB-038634, HY-B0180, MSK10029, Tox21_110985, AC-529, BBL010772, BDBM50240849, EBC-07888, HB3109, NSC759651, NSC811538, NSC828389, s1211, STK583860, Imiquimod - CAS 99011-02-6, Imiquimod, >=98% (HPLC), solid, AKOS005507352, Tox21_110985_1, 1H-Imidazo[4, 1-(2-methylpropyl)-, CCG-208015, CS-2058, DB00724, FI24563, KS-5218, NSC 369100, NSC 741062, NSC 759651, NSC-811538, NSC-828389, YH44175, Imiquimod 100 microg/mL in Acetonitrile, NCGC00070736-03, NCGC00070736-04, BI164576, SMR000048307, SY017571, I0747, NS00006714, D02500, 1-isobutyl-1H-imidazo [4,5-c]quinolin-4-amine, 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine, AB00399298-05, AB00399298-06, AB00399298-07, AB00399298_08, AB00399298_09, EN300-6477856, 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-ylamine, F386709, Q423417, SR-01000611320-2, SR-01000611320-3, BRD-K26657438-001-01-2, BRD-K26657438-001-13-7, BRD-K26657438-001-15-2, BRD-K26657438-001-17-8, BRD-K26657438-003-01-8, 1-(2-methylpropyl)-1Himidazo[4,5-c]quinolin-4-amine, Z2588038940, 1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine, Imiquimod, United States Pharmacopeia (USP) Reference Standard
Theoretical properties:
molecular_formula: C14H16N4
molecular_weight: 240.30 g/mol
exact_mass: 240.137496527 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 2
heavy_atom_count: 18
topological_polar_surface_area: 56.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Crystals from DMF
color: Crystals from DMF
melting_point: 292-294 °C
solubility: Poorly soluble
Descriptions:
pubchem: Imiquimod is an imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis. It has a role as an antineoplastic agent and an interferon inducer.
chebi: An imidazoquinoline fused [4,5-<em>c</em>] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.
chembl: IMIQUIMOD is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Imiquimod, sold under the brand name Aldara among others, is a medication that acts as an immune response modifier that is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.
Scientists at 3M's pharmaceuticals division discovered the drug and 3M obtained the first FDA approval in 1997. As of 2015, imiquimod is generic and is available worldwide under many brands. In 2021, it was the 290th most commonly prescribed medication in the United States, with more than 600,000 prescriptions.